In humans, the effects of the octapeptide hormone angiotensin II (AngII) are mediated by two types of AngII receptors, AT~1~R and AT~2~R, which share approximately 34% amino acid sequence identity^[@R1],[@R2]^. AT~1~R is mainly responsible for blood pressure regulation, with several antagonists and inverse agonists approved for clinical use as anti-hypertensive drugs^[@R3]^. The function of AT~2~R, on the other hand, is less understood and remains controversial, with a growing number of studies suggesting that AT~2~R signals primarily via non-canonical, G protein- and β-arrestin-independent pathways^[@R4],[@R5]^. In the cardiovascular system, AT~2~R has been reported to counteract several of the effects mediated by AT~1~R^[@R6],[@R7]^, conferring cardioprotection. For example, in vasculature AT~2~R has been suggested to counter-balance blood pressure elevation exerted by AT~1~R^[@R8],[@R9]^. It has also been reported that activation of AT~2~R in cardiomyocytes inhibits autophagy mediated by AT~1~R^[@R10]^. Moreover, in the central nervous system, AT~2~R has been implicated in AT~1~R-independent signaling pathways^[@R11]--[@R14]^. It has been observed that activation of AT~2~R in nociceptive neurons induces neurite outgrowth and elongation^[@R15]^, while studies in sensory neurons selectively expressing AT~2~R but not AT~1~R, also supported involvement of AT~2~R in nociception^[@R16]--[@R18]^. Further interest in AT~2~R as a drug target has been sparkled by the recent finding that the canonical AT~2~R antagonist PD123319 blocks AngII-induced neuronal excitability, and exhibits oral bioavailability in several neuropathic pain models in rodents^[@R17]--[@R19]^. Most excitingly, EMA401, an analog of PD123319, demonstrated efficacy in phase II clinical trials in patients with post-herpetic neuralgia^[@R16],[@R20]^. Interestingly, activation of AT~2~R by its small molecule agonist Compound 21 (ref. [@R21]) has also been reported to produce a number of beneficial *in vivo* effects such as inducing pressure natriuresis, lowering blood pressure, conferring acute vaso-relaxation, and exhibiting organ protective effects^[@R22],[@R23]^.

We previously reported crystal structures of AT~1~R in complex with an antagonist ZD7155 (ref. [@R24]) and with an inverse agonist olmesartan^[@R25]^, which provided insights into AT~1~R receptor-ligand interactions. The molecular mechanisms of functional diversity and ligand selectivity between AT~1~R and AT~2~R, however, remain elusive. With an increasing body of evidence indicating that selective targeting of AT~2~R could be used for cardioprotection and for the treatment of neuropathic pain, there is an imminent need to elucidate the structural basis for the functional role of this receptor, and to develop type-selective ligands. In this study, we determined crystal structures of AT~2~R bound to two high-affinity ligands, an AT~2~R-selective ligand compound **1** (Cpd **1**)^[@R26]^ and an AT~1~R/AT~2~R-dual ligand compound **2** (Cpd **2**)^[@R27]^. Both compounds are derivatives of a series of small-molecule antagonists of AT~1~R and thus could be assumed to exert the same function in AT~2~R. However, classification of compounds using traditional G protein-coupled receptor (GPCR) nomenclature into antagonists or agonists has proven difficult for AT~2~R since it has not been reliably demonstrated to signal through any of the canonical GPCR signaling pathways involving G proteins or β-arrestin. Furthermore, it has been observed numerous times that small changes to the structures of closely related compounds can lead to changes or bias in function^[@R28],[@R29]^. Therefore, we refer to Cpd **1** and Cpd **2** using the neutral term 'ligand'. In addition to a dramatic reshaping of the ligand-binding pocket between the two receptors, our AT~2~R structures revealed an active-like conformation of the seven-transmembrane (7TM) helical bundle with a non-canonical positioning of the amphipathic helix VIII, potentially blocking recruitment of intracellular signaling partners.

Structure determination {#S2}
=======================

The human AT~2~R construct used for structure determination was engineered to facilitate crystallization ([Extended Data Fig. 1](#F5){ref-type="fig"}) by truncating the N-terminal residues 1--34 and the C-terminal residues 336--363, and fusing a thermostabilized apocytochrome *b*~562~RIL^[@R30]^ to the truncated N-terminus via a 4-residue linker. Compared to wild-type AT~2~R, the engineered receptor showed no significant difference in the binding to small molecule ligands (Cpds **1** and **2**) as determined by radio-ligand binding assays ([Extended Data Fig. 2a,c,d](#F6){ref-type="fig"}). In contrast, the affinities of the peptides AngII and Sar^1^-Ile^8^-AngII were slightly lower (\~3-fold), a potential consequence of the N-terminal truncation ([Extended Data Fig. 2b](#F6){ref-type="fig"}). AT~2~R bound to the selective ligand Cpd **1** generated a high density of microcrystals in lipidic cubic phase (LCP)^[@R31]^ with an average size of 5×2×2 μm^3^ ([Extended Data Fig. 3a](#F7){ref-type="fig"}). These microcrystals were used to collect serial femtosecond crystallography (SFX)^[@R32]--[@R34]^ data at an X-ray free-electron laser (XFEL), resulting in two 2.8 Å resolution room temperature structures solved in monoclinic and orthorhombic space groups, respectively ([Extended Data Table 1](#T1){ref-type="table"}). In parallel, we solved another AT~2~R structure in complex with the non-selective AT~1~R/AT~2~R dual ligand Cpd **2** at 2.9 Å resolution ([Extended Data Table 1](#T1){ref-type="table"}) by synchrotron radiation, using cryo-cooled crystals with an average size of 70×40×20 μm^3^ ([Extended Data Fig. 3b](#F7){ref-type="fig"}). All three AT~2~R structures showed nearly identical conformations of the receptor (RMSD~Cα~ \< 0.5 Å). Since the orthorhombic AT~2~R-Cpd **1** structure is the most complete, we used it for the description of the overall AT~2~R structure below, unless noted otherwise.

Active-like conformation of 7TM bundle {#S3}
======================================

The overall architecture of AT~2~R is comprised of a 7TM bundle (helices I--VII) and an intracellular amphipathic helix VIII ([Fig. 1a](#F1){ref-type="fig"}). Similar to AT~1~R and other peptide-binding GPCRs^[@R24]^, AT~2~R exhibits a β-hairpin conformation of the extracellular loop 2 (ECL2) and two pairs of disulfide bonds linking the N-terminus with ECL3 (Cys35^N-term^-Cys290^ECL3^), and helix III with ECL2 (Cys117^3.25^-Cys195^ECL2^, superscripts indicate residue numbers as per the Ballesteros-Weinstein nomenclature^[@R35]^). A closer comparison of the AT~1~R and AT~2~R structures, however, revealed substantially different conformations ([Fig. 1b--e](#F1){ref-type="fig"}). While the previously determined AT~1~R structures captured the receptor in a classical inactive state, all three AT~2~R structures, obtained in this work, display an active-like conformation. Specifically, the intracellular end of helix VI shows an outward displacement by \~11.5 Å, whereas the intracellular end of helix VII exhibits an inward displacement by \~4.9 Å, as compared to the structures of inactive AT~1~R ([Fig. 1e](#F1){ref-type="fig"}). Similar large-scale shifts of helices VI and VII that open an intracellular cleft for the recruitment of G proteins/β-arrestins have been implicated in activation of all class A GPCRs^[@R36],[@R37]^. Another major conformational rearrangement occurs at the extracellular end of helix V, which is shifted toward the ligand-binding pocket by \~4.8 Å, compared to AT~1~R ([Fig. 1d](#F1){ref-type="fig"}). Similar shifts of the extracellular part of helix V, although typically with a smaller \~2 Å amplitude, have been observed in structures of several activated GPCRs, such as the β~2~-adrenergic (β~2~AR) and serotonin 5-HT~2B~ receptors^[@R38],[@R39]^. Such agonist-stabilized displacement of helix V is critical for triggering re-arrangements in the P^5.50^-I^3.40^-F^6.44^ motif leading to activation of these receptors^[@R38]--[@R40]^.

The large-scale re-arrangements of helices during activation are accompanied by conformational changes in the conserved micro-switches^[@R36]^. We therefore compared the DR^3.50^Y, NP^7.50^xxY, and P^5.50^-I^3.40^-F^6.44^ motifs of AT~2~R with those in the structures of inactive AT~1~R and of fully activated GPCRs, such as G~s~ protein-bound β~2~AR^[@R38]^ and arrestin-bound rhodopsin^[@R38],[@R41]^. The large-scale movement of helix VI upon activation is enabled by re-arrangements in the P^5.50^-I^3.40^-F^6.44^ motif (Pro223^5.50^-Ile132^3.40^-Phe265^6.44^ in AT~2~R) as it was previously demonstrated in other structures of activated GPCRs ([Fig. 1c](#F1){ref-type="fig"}). In the DR^3.50^Y motif, the Arg142^3.50^ side chain of AT~2~R is rotated by \~90° compared to Arg126^3.50^ in AT~1~R, adopting a similar conformation as in other fully activated GPCRs. Additionally, in the NP^7.50^xxY motif, the side chain of Tyr318^7.53^ is shifted by \~6.5 Å and rotated by \~45° from the corresponding position of Tyr302^7.53^ in AT~1~R, following the inward movement of helix VII, as observed in other receptors upon activation. Finally, analysis of the conserved residue switch^[@R37]^ in the G protein-binding pocket L\[M\]^3.46^--I\[A\]^6.37^--Y\[Y\]^7.53^ (AT~2~R residues are shown in brackets) confirms the rearrangement of interactions in this residue triad consistent with an active-like state of AT~2~R ([Extended Data Fig. 4a,b](#F8){ref-type="fig"}). Interestingly, instead of a highly conserved large hydrophobic residue in position 6.37, AT~2~R has a rare alanine residue (\~3% of class A GPCRs), which drastically reduces the hydrophobic contact area between helices III and VI in the inactive state, and likely facilitates the activation related changes in AT~2~R. Therefore, all of the major conformational features indicate that the 7TM bundle of AT~2~R adopts an active-like conformation, similar to that observed in the crystal structures of other fully activated class A GPCRs bound to signaling partners or their mimics.

In addition to the conserved micro-switches, a sodium-binding site consisting of sixteen highly conserved residues is expected to undergo large-scale conformational changes upon activation of class A GPCRs^[@R42]^. Superposition of AT~2~R with AT~1~R revealed that the putative sodium-binding pocket in AT~2~R is collapsed and rearranged, hindering sodium ion binding ([Extended Data Fig. 4c,d](#F8){ref-type="fig"}), primarily due to the inward shift of helix VII, which is consistent with the structures of other activated GPCRs^[@R42]^. Only two out of sixteen residues in the putative sodium pocket (Ile135^3.43^ and Ser311^7.46^) are different from their counterparts in AT~1~R (Leu119^3.43^ and Asn295^7.46^). Interestingly, Asn295^7.46^Ala mutation was implicated in the AT~1~R constitutive activation^[@R43],[@R44]^, potentially due to the disruption of two hydrogen bonds between Asn295^7.46^ and Asn111^3.35^ that stabilize the inactive conformation. In contrast, Ser311^7.46^ in AT~2~R cannot engage in a similar interaction with Asn127^3.35^, potentially shifting the conformational equilibrium toward the active state. Indeed, AT~2~R has been reported to have high constitutive activity, and to induce apoptosis even in the absence of AngII stimulation^[@R45],[@R46]^.

Helix VIII blocks putative G protein/β-arrestin binding site {#S4}
============================================================

In most GPCR structures, helix VIII lies parallel to the membrane pointing outside of the 7TM bundle^[@R24]^, regardless of the receptor's activation state ([Fig. 2a,b](#F2){ref-type="fig"}). Surprisingly, in the AT~2~R structures helix VIII adopts a very different conformation by flipping over to interact with the intracellular ends of helices III, V, and VI ([Fig. 2c](#F2){ref-type="fig"}). This non-canonical conformation of helix VIII was found in all AT~2~R structures determined in this study, regardless of the ligand identity and different crystal packing environments ([Extended Data Fig. 3c--e](#F7){ref-type="fig"}), suggesting it to be likely a genuine feature of AT~2~R, rather than an artifact of crystallization. Helix VIII forms a highly complementary interface with the intracellular cavity of the 7TM bundle, stabilized by extensive hydrophobic interactions mediated by Phe325^8.50^, Leu329^8.54^, Val332^8.57^, and Phe333^8.58^, as well as by polar interactions between Arg324^8.49^, Gln326^8.51^, and Lys328^8.53^, and helices III, V, and VI ([Fig. 2d](#F2){ref-type="fig"}). Docking and molecular dynamics (MD) simulations suggest that helix VIII stabilizes the active-like conformation of the 7TM bundle of AT~2~R, while sterically blocking the binding of G proteins and β-arrestins ([Fig. 2c](#F2){ref-type="fig"}), which is consistent with the lack of robust downstream signaling by AT~2~R as assessed by traditional G protein and β-arrestin assays^[@R4],[@R5]^. In MD simulations, helix VIII not only remained in the range of positions within RMSD \< 4 Å to the crystallographic structure for a total of 4 μs of unbiased simulation ([Extended Data Fig. 5a--c](#F9){ref-type="fig"}), but also quickly (\< 200 ns) and reproducibly (n=4) returned to this conformation after consequent pertubations of its position ([Extended Data Fig. 5d,e](#F9){ref-type="fig"}). Alternatively, when helix VIII was relocated to the position observed in the AT~1~R structures, it relaxed into a canonical membrane-bound conformation, and this motion was accompanied by an inward shift of the intracellular tip of helix VI towards its position in the inactive state AT~1~R structure in three out six independent MD runs ([Extended Data Fig. 5f--h](#F9){ref-type="fig"}).

Insights into AT~1~R/AT~2~R ligand selectivity {#S5}
==============================================

Many AT~1~R and AT~2~R ligands share a biphenyl-tetrazole scaffold important for ligand binding affinity. However, molecular mechanisms for ligand selectivity between the two types of angiotensin receptors remain elusive. Our radioligand competition binding studies with Cpd **2** obtained *K~i~* values of 3.7 nM and 0.35 nM for binding to AT~1~R and AT~2~R, respectively, indicating this compound is a dual ligand with only about 10-fold selectivity for AT~2~R over AT~1~R. In contrast, Cpd **1** exhibited an approximately 530-fold selectivity towards AT~2~R, with *K~i~* values of 180 nM and 0.34 nM for AT~1~R and AT~2~R, respectively ([Extended Data Fig. 2c,e](#F6){ref-type="fig"}).

In all three AT~2~R structures, strong electron density was observed in the orthosteric ligand-binding pocket enabling accurate placement of both Cpds **1** and **2 (**[Extended Data Fig. 6](#F10){ref-type="fig"}). We compared the positions and interactions of these compounds bound to AT~2~R with two ligands bound to AT~1~R (the AT~1~R selective antagonist ZD7155, and the AT~1~R selective inverse agonist olmesartan) ([Fig. 3](#F3){ref-type="fig"}). Surprisingly, despite the common scaffold the ligands bind to the two receptor types very differently, with only the tetrazole moieties partially overlapping and forming critical hydrogen bonds with an arginine in ECL2 (Arg167^ECL2^ in AT~1~R and Arg182^ECL2^ in AT~2~R). The overall biphenyl-tetrazole scaffold of the AT~2~R-bound ligands, however, is rotated about 45° as compared to its orientation in the AT~1~R-bound ligands, forming a distinct interaction pattern ([Fig. 3a](#F3){ref-type="fig"}). Interestingly, Arg^ECL2^, Tyr^1.39^, and Trp^2.60^, previously identified as key residues for ligand binding in AT~1~R, also provide critical protein-ligand contacts in AT~2~R, although with different side chain conformers. The side chain of Trp100^2.60^ in AT~2~R is shifted \~3.1 Å compared to Trp84^2.60^ in AT~1~R to form hydrophobic interactions with the thiophene ring of Cpd **1** and the benzene ring of Cpd **2**, both on the carbonyl side of the AT~2~R ligands. On the other side of the carbonyl moiety, Thr88^2.64^ in AT~1~R is replaced with Tyr104^2.64^ in AT~2~R that forms new hydrophobic interactions with the benzene ring of Cpd **1** and the furan ring of Cpd **2**. Moreover, the tetrazole moiety of the AT~2~R ligands is engaged in new polar interactions with Lys215^5.42^, Thr125^3.33^ and Thr178^4.60^ side chains, in addition to Arg182^ECL2^. The bottom part of the ligand-binding pocket in AT~2~R is expanded due to a smaller side chain of Leu93^2.53^ compared to Phe77^2.53^ in AT~1~R and a \~5.2 Å shift of Phe308^7.43^ compared to Tyr292^7.43^ in AT~1~R ([Fig. 3b, c](#F3){ref-type="fig"}). In AT~1~R, Tyr292^7.43^ forms a hydrogen bond with the backbone of helix III, while in AT~2~R, Phe308^7.43^ is unable to form this interaction and is shifted over in concert with a pronounced shift in the backbone of helix VII. This rearrangement opens a sub-pocket for the binding of the ethyl and propyl moieties of Cpds **1** and **2**. Overall, these changes result in different shapes of the ligand-binding pocket between the two angiotensin receptors and a deeper ligand binding in AT~2~R.

To gain additional insights into receptor type selectivity, we modeled an active-like state for AT~1~R and an inactive state for AT~2~R, and performed unrestrained cross-docking of ZD7155, olmesartan, Cpds **1** and **2** into the crystal structures and models of both receptors ([Extended Data Fig. 7](#F11){ref-type="fig"}). The results suggest that while the conformational state of AT~2~R has little effect on the ligand binding, the predicted active-like conformation of AT~1~R is not compatible with binding of any of the tested ligands, corroborating the status of these ligands as antagonists for AT~1~R. Furthermore, the binding modes of these ligands are imposed by the distinct shapes of the binding pockets of the two receptors. Indeed, the biphenyl-tetrazole moieties of Cpds **1** and **2** docked to AT~1~R crystal structure strongly preferred binding modes similar to those of olmesartan and ZD7155 ([Extended Data Fig. 7a,b](#F11){ref-type="fig"}). The only differences were observed in the orientation of the benzene and heterocyclic rings of Cpds **1** and **2**, which occupy the upper part of the ligand-binding pocket, beyond the interaction site of olmesartan and ZD7155. Similarly, docking into the AT~2~R structure suggested that ZD7155 and olmesartan can fit in the AT~2~R pocket, with their biphenyl-tetrazole scaffolds closely following the scaffolds of Cpds **1** and **2** in the corresponding AT~2~R crystal structures. Although docking supports binding of all four ligands in both AT~1~R and AT~2~R crystal structures, the binding scores of the ligands vary significantly, reflecting different interactions of non-scaffold groups. The scores also qualitatively reflect differences in the affinities of these compounds, with the cognate ligands showing substantially better binding scores than the off-target binders.

Mutagenesis of the ligand-binding pocket validates crystal structures {#S6}
=====================================================================

Point mutations were introduced in 17 residues of the AT~2~R ligand-binding pocket and their effects on ligand affinity were assessed for \[^3^H\]AngII peptide, as well as for the small molecule Cpds **1** and **2** in \[^3^H\]AngII competition assays ([Supplementary Discussion](#SD1){ref-type="supplementary-material"} and [Extended Data Fig. 8](#F12){ref-type="fig"}).

Overall, the effects of mutations in the binding pocket of AT~2~R are consistent with the receptor-ligand interactions observed in the co-crystal structures with Cpds **1** and **2**. At the same time, most of these effects are distinct from the effects in AT~1~R-sartan complexes, corroborating the substantial differences in the ligand binding modes between AT~2~R and AT~1~R. Note that the effects of binding pocket mutations are practically identical for Cpds **1** and **2**, with the only notable exception of Trp269^6.48^Phe modestly (\~5-fold) affecting affinity of Cpd **1**, but not of Cpd **2**.

SAR provides further insights into receptor selectivity {#S7}
=======================================================

The structure-activity relationship (SAR) of Cpd **1** analogs was studied using derivatization of the 3- (**R~1~)** and 7- (**R~2~)** positions of the quinazolinone core ([Extended Data Table 2](#T2){ref-type="table"}), and its structural basis was analyzed by molecular docking to the AT~1~R and AT~2~R crystal structures ([Fig. 4](#F4){ref-type="fig"}). The SAR dataset comprised a series of 14 compounds spanning a wide range of selectivity for the two receptor types. Two members of the series were found to be highly selective for AT~2~R (530-fold for Cpd **1** and 410-fold for Cpd **3**), while two others showed a high degree of selectivity for AT~1~R (1,120-fold for Cpd **9** and 180-fold for Cpd **13**). The remaining compounds exhibited moderate (\<15 fold) to no selectivity.

The SAR data showed that the **R~1~** substituent is critical for high AT~2~R selectivity, while the **R~2~** substituent mostly defines a high selectivity towards AT~1~R ([Extended Data Table 2](#T2){ref-type="table"}). Despite the dramatic differences in the pocket shapes and ligand-binding poses between AT~2~R and AT~1~R, the docking results provide important insights into the structural basis of SAR observations and directions for optimization of AT~2~R selective ligands (see [Supplementary Discussion](#SD1){ref-type="supplementary-material"}).

Conclusions {#S8}
===========

The two types of the AngII receptor are distinct in terms of their genetic variations, tissue specific expression, signaling, and regulation, as well as other physiological and pharmacological properties^[@R1],[@R47]^. Although all of the conserved motifs of class A GPCRs are present in AT~2~R, it exhibits an atypical behavior compared to other receptors^[@R1]^. Discerning the AT~2~R-specific signaling pathways has been challenging and remains unresolved to date^[@R4],[@R5]^. The features revealed in the AT~2~R structures reported here might provide potential explanations for its poor coupling to G proteins/β-arrestins. Based on our results, we hypothesize that helix VIII can play a dual role in the modulation of AT~2~R function. On the one hand, upon adopting a conformation captured in the crystal structures, helix VIII may stabilize an active-like receptor state, while repressing canonical AT~2~R activity in a self-inhibitory manner by sterically blocking the G protein/β-arrestin binding site. On the other hand, upon switching to a membrane-bound conformation helix VIII can support the recruitment of G proteins/β-arrestins for AT~2~R signaling. Therefore, helix VIII may work as a gatekeeper for either suppression or activation of the receptor depending on its post-translational modifications and interactions with various receptor partners and its environment. This hypothesis is consistent with the previously observed failure of AT~2~R to internalize, thus prolonging biological responses without desensitization^[@R48],[@R49]^. Further investigation is needed to fully understand this phenomenon.

Both AngII receptors are important drug targets, since the blockade of AT~1~R has anti-hypertensive effects, while the modulation of AT~2~R could be useful for cardioprotection, neuropathic pain relief and treatment of a variety of other conditions. Designing molecules that selectively bind to a specific receptor type is often challenging but can be critical for different therapeutic purposes. Although the AT~1~R and AT~2~R ligands share common scaffolds, the ligand-binding pockets of these two receptors are strikingly different, and these differences could be exploited for designing selective ligands. The AT~2~R crystal structures determined in this study improve our understanding of the two types of the human angiotensin receptors and provide new insights into the structural basis for the binding and selectivity of small molecules of therapeutic significance. Our results are therefore expected to facilitate the rational structure-based drug design for improved selectivity.

METHODS {#S9}
=======

No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.

Protein engineering for structural studies {#S10}
------------------------------------------

DNA encoding the human AT~2~R (UNIPROT P50052) was synthesized by GenScript with optimization for expression in insect cells. The construct has truncations of the AT~2~R residues 1--34 and 336--363. The thermostabilized apocytochrome *b*~562~RIL (BRIL) from *E. coli* with mutations Met7Trp, His102Ile, and Arg106Leu was fused to the N-terminus of AT~2~R, with a 4-residue linker (Gly-Ser-Gly-Ser). The BRIL-AT~2~R chimera sequence was subcloned into vector **pFastBac1** (Invitrogen), with N-terminal haemagglutinin (HA) signal sequence, a FLAG tag, a 10×His tag, and a tobacco etch virus (TEV) protease cleavage site.

Protein expression and purification {#S11}
-----------------------------------

The BRIL-AT~2~R protein was expressed in *Spodoptera frugiperda* (*Sf*9) insect cells (ATCC CRL-1711) using the Bac-to-Bac baculovirus expression system (Invitrogen). Cells were lysed by repeated washing and centrifugation, with hypotonic buffer (10 mM HEPES, pH 7.5, 10 mM MgCl~2~, 20 mM KCl) and high osmotic buffer (10 mM HEPES, pH 7.5, 1.0 M NaCl, 10 mM MgCl~2~, 20 mM KCl), adding EDTA-free complete protease inhibitor cocktail tablets (Roche). The washed membranes were suspended in hypotonic buffer with 2 mg/ml iodoacetamide for 30 min at 4 °C, and then solubilized in 100 mM HEPES, pH 7.5, 800 mM NaCl, 0.5% (w/v) n-dodecyl-beta-D-maltopyranoside (DDM, Anatrace), 0.1% (w/v) cholesterol hemisuccinate (CHS, Sigma-Aldrich), and 10% (v/v) glycerol, for 4 hours at 4 °C. The solubilized BRIL-AT~2~R protein was then bound to TALON IMAC resin (Clontech) overnight. The resin was washed with 10 column volumes of wash buffer I (50 mM HEPES, pH 7.5, 400 mM NaCl, 5% (v/v) glycerol, 0.1% (w/v) DDM, 0.02% (w/v) CHS, 10 mM imidazole), and 10 column volumes of wash buffer II (20 mM HEPES, pH 7.5, 200 mM NaCl, 5% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 20 mM imidazole). The BRIL-AT~2~R protein was eluted by 3 column volumes of elution buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 5% (v/v) glycerol, 0.02% (w/v) DDM, 0.004% (w/v) CHS, 300 mM imidazole), then incubated with 100 μM of ligand (Cpd **1** or **2**), treated overnight with TEV protease to remove tags, and concentrated to 15 mg/ml with a 100 kDa cutoff concentrator (Vivaspin). The protein yield and monodispersity were tested by analytical size exclusion chromatography (aSEC).

Lipidic cubic phase crystallization {#S12}
-----------------------------------

The AT~2~R protein was reconstituted in lipidic cubic phase (LCP) by mixing the protein with monoolein supplemented with 10% cholesterol at a protein/lipid ratio of 2:3 (v/v) using a lipid syringe mixer. Crystallization trials were performed with an NT8-LCP robot (Formulatrix) in 96-well glass sandwich plates (Marienfeld) using 40 nL protein-loaded LCP and 800 nL precipitant solution per well. Plates were stored at 20 °C and imaged using a RockImager 1000 (Formulatrix). Crystals of AT~2~R-Cpd **2** grew to an average size of 70×40×20 μm^3^ within 21 days in 100 mM Tris-HCl, pH 8.0, 25--100 mM potassium formate, 25--35% (v/v) PEG400, and 0.3--1.2% (w/v) 1,6-hexanediol. Crystals were harvested using micromounts (MiTeGen) directly from LCP and flash-frozen in liquid nitrogen for diffraction data collection at the synchrotron radiation beamline. Micro-crystals of AT~2~R-Cpd **1** for XFEL data collection were prepared by injecting 5 μl protein-laden LCP aliquots into 100 μl gas-tight syringes filled with 60 μl precipitant solution (100 mM Tris-HCl, pH 8.0, 25 mM potassium formate, 25% (v/v) PEG400, and 0.3% (v/v) (+/−)-2-Methyl-2,4-pentanediol). The crystals grew to an average size of 5×2×2 μm^3^ within 5 days at 20 °C. Before loading the micro-crystals into the LCP injector, the excess precipitant solution was carefully removed from the syringes, and the remaining LCP with embedded crystals was consolidated together. Approximately 20% (v/v) 7.9 MAG was added and mixed with the LCP, to absorb the residual precipitant solution and prevent the formation of lamellar crystalline phase due to rapid evaporative cooling when injecting LCP into vacuum^[@R34]^.

Diffraction data collection using synchrotron radiation {#S13}
-------------------------------------------------------

Crystallographic diffraction data collection was performed at 23ID-D beamline (GM/CA) of the Advanced Photon Source in the Argonne National Laboratory. Diffraction data from 47 crystals of AT~2~R-Cpd **2** were collected using a Pilatus3 6M detector with an unattenuated 10 μm minibeam (wavelength 1.0330 Å). Data were collected using 2 s exposure and 0.5° oscillation with the maximum wedge of 20° per crystal, and then integrated, scaled and merged using XDS^[@R50]^.

Diffraction data collection using X-ray free-electron laser {#S14}
-----------------------------------------------------------

Serial Femtosecond Crystallography (SFX) data collection was performed using the CXI instrument at the Linac Coherent Light Source (LCLS) at SLAC National Accelerator Laboratory. The LCLS was operated at a wavelength of 1.3 Å (9.57 keV) delivering individual X-ray pulses of 40 fs pulse duration and \~10^11^ photons per pulse focused into a spot size of approximately 1.5 μm in diameter using a pair of Kirkpatrick-Baez mirrors. Microcrystals of AT~2~R-Cpd **1** were delivered in the LCP media using a microextrusion injector^[@R34]^ with 50 μm nozzle running at \~220 nL/min flow rate. Diffraction images were recorded at a rate of 7,200 patterns per minute (120 Hz) with the 2.3 Megapixel Cornell-SLAC Pixel Array Detector (CSPAD). A total of 2,701,530 images were collected, 175,241 of which were identified as hits with the Cheetah program (6.5% hit rate). Surprisingly, indexing revealed two different lattices, monoclinic and orthorhombic, apparently belonging to different microcrystals of AT~2~R-Cpd **1** co-existing in the same crystallization batch. Therefore, 22,774 hits were successfully indexed in a *2/m* Laue group and 15,804 hits in a *mmm* Laue group with different lattice parameters. Both datasets were merged separately using the standard CrystFEL pipeline^[@R51]^ of Monte Carlo averaging without additional scaling step applying per-pattern resolution cutoff with '*pushres* 1.2' option.

Structure determination {#S15}
-----------------------

The structure was initially solved using molecular replacement (MR) with the monoclinic data sets collected at XFEL and synchrotron source. MR models for AT~2~R were produced by alignment of AT~2~R sequence with sequences of previously solved GPCRs. The top 20 templates were further edited to preserve the conserved residues and trim non-conserved residues to alanines. MR search with Phaser^[@R52]^ identified locations of two receptors in asymmetric unit with a TFZ \> 9. Further MR search with fixed positions of the two receptors using PDB ID 1MT6 as the search model for BRIL found one BRIL molecule in the asymmetric unit. Refinements and model completion were performed by repetitive cycling between Refmac5 and autoBUSTER, followed by manual examination and rebuilding of the refined coordinates in Coot^[@R53]^, using both 2mFo-DFc and mFo-DFc maps, as well as omit maps calculated using Bhat's procedure^[@R54]^. The second BRIL molecule was modeled manually in the available electron density when Rfree dropped below 0.33. The final data collection and refinement statistics are shown in [Extended Data Table 1](#T1){ref-type="table"}. The Ramachandran statistics determined by MolProbity^[@R55]^ are as follows: 96.8% in favored region, 3.2% allowed, 0 outlier for monoclinic AT~2~R-Cpd **1**; 97.6% in favored region, 2.4% allowed, 0 outlier for orthorombic AT~2~R-Cpd **1**; 97.4% in favored region, 2.6% allowed, 0 outlier for AT~2~R-Cpd **2**.

Docking simulations {#S16}
-------------------

AT~1~R and AT~2~R selective and non-selective ligands were docked into the AT~1~R and AT~2~R crystal structures, AT~1~R active-like state and AT~2~R inactive state models using an energy-based docking protocol implemented in ICM molecular modeling software (Molsoft, LLC). The structures of the receptors were protonated and optimized using an ICM docking pipeline. The active and inactive state receptor models were obtained using homology modeling algorithm implemented in ICM. Crystal structures of AT~2~R and AT~1~R were used as templates for the AT~1~R active-like state model and the AT~2~R inactive state model, respectively. Molecular models of the compounds were generated from two-dimensional representations and their 3D geometry was optimized using MMFF-94 force field^[@R56]^. Molecular docking employed biased probability Monte Carlo (BPMC) optimization of the ligand internal coordinates in the grid potentials of the receptor^[@R57]^. To ensure exhaustive sampling of the ligand binding pose parameter thoroughness was set to 30 and at least five independent docking runs were performed for each ligand starting from a random conformation. The results of individual docking runs for each ligand were considered consistent if at least three of the five docking runs produced similar ligand conformations (RMSD \< 2.0 Å) and binding score \< −25.0 kJ/mol. The unbiased docking procedure did not use distance restraints or any other a priori derived information for the ligand-receptor interactions.

Molecular dynamics {#S17}
------------------

The initial receptor coordinates were derived from the AT~2~R crystal structures in complexes with Cpd **1** and Cpd **2**. The N-terminal fusion partner BRIL was removed and the terminal amino acids Cys35 and Arg337 were acetylated and amidated, respectively. We used ICM-Pro package ([www.molsoft.com](www.molsoft.com)) to construct the model in the regions of missing electron densities for side chains and especially for the intracellular loop (ICL) regions. The orientations of AT~2~R in the apo and the ligand bound models were aligned to AT~1~R orientation in the membrane taken from the OPM database ([www.opm.phar.umich.edu](www.opm.phar.umich.edu)).

Initial ligand parameterization was performed in CGenFF available with CHARMM-GUI interface^[@R58]^. For corrections in charge assignments with high penalty values, Cpd **1** and Cpd **2** were fragmented and re-parameterized using Gaussian03 package and Force Field Tool-Kit available with VMD v.1.9.2^[@R59]^. CHARMM36 additive force field was used for rest of the system^[@R60]^. We used homogenous lipid bilayer of 164 palmitoyloleoylphosphatidylcholine (POPC) lipids. TIP3P water model used for solvation of the lipids-receptor-ligand system with 150 mM salt concentration of Na^+^ and Cl^−^.

The initial input files generated using CHARMM-GUI interface were simulated using GROMACS v5.0.4 molecular simulation package compiled to run in parallel computing architecture using multiple GPUs ^[@R61]^. Each simulation was performed on a cluster of 4 nodes connected via InfiniBand, where a single node had 16 Intel Xeon 2.4 GHz processors and 2 NVIDIA Tesla K20 GPUs. Simulation parameters include a 1 fs (femtosecond) time step for the first step of the equilibration, followed by a 2 fs time step for the rest of the equilibration and production simulations. During initial phase of NVT ensemble, temperature was set at 310 K using Berendsen thermostat^[@R62]^, and the initial harmonic restraints of 10.0 kCal /mol/Å^2^ applied for protein and lipid heavy atoms. These restraints were gradually reduced throughout the equilibration phase, followed by a production phase with no restraints. In the production phase of NPT ensemble, the pressure was set to 1 bar using Parrinello-Rahman barostat and 310 K temperature with Nose-Hoover thermostat. Non-bonded interaction calculations cut-off was set at 12 Å. The Particle mesh Ewald (PME) FFT grid was used with a dimension of 64×64×96 for all simulations. Bond lengths to H-atoms were constrained using P-LINCS algorithm^[@R63]^.

A total of 10.2 μs of production MD simulation were performed to study the interactions of Helix VIII in AT~2~R, including 8 runs of 0.5 μs each for crystal structure starting conformations, 8 × 0.25 μs for perturbed position of helix VIII, and 6 × 0.7 μs for AT~1~R-like starting conformation of helix VIII. Simulation trajectories were analyzed using GROMACS and VMD^[@R59]^. Plots and images were generated using Grace (<http://plasma-gate.weizmann.ac.il/Grace>) and ICM-Pro.

Radioligand binding assays {#S18}
--------------------------

Radioligand binding studies were performed using mammalian virus-like particles (VLPs) containing wild-type AT~1~R, wild-type AT~2~R, or the engineered BRIL-AT~2~R. VLPs were produced using the Expi293 MembranePro Expression System (ThermoFisher) per the manufacturer's instructions. Total protein concentration was determined by Bradford assay. VLPs were re-suspended in cold Dulbecco's Phosphate-Buffered Saline (PBS) without calcium or magnesium (Gibco). Aliquots were flash-frozen and stored at −80 °C. All binding reactions were carried out in 96-well microplates (Corning). The assay buffer (50 μL) consisted of 20 mM HEPES pH 7.4, 5 mM MgCl~2~, 1 mM EDTA, and 0.005 % Tween-20. Non-specific binding was determined in the presence of 1 μM AngII. Final concentrations of \[^125^I\]-Sar^1^-Ile^8^-AngII (Perkin Elmer) were typically 0.05--5 nM in saturation and 0.3 nM in competition binding experiments. For both types of assays, 37.5 ng (wild-type AT~1~R or engineered BRIL-AT~2~R) or 13.5 ng (wild-type AT~2~R) VLPs were used per well. Competing ligands were added as DMSO solutions, resulting in a total organic solvent content of 1 %. Reactions were incubated for 3 hours at room temperature. Bound ligand was separated from free ligand by processing 25 μL of each reaction mixture on 96-well Zeba Spin desalting plates with a molecular weight cut-off of 40 kDa (ThermoScientific) according to the manufacturer's instructions. Eluates were collected in isoplates-96 microplates by centrifugation (100 × g for 3 min) and bound ligand was quantitated after addition of 150 μL of UltimaGold MV scintillation fluid on a Perkin Elmer Wallac Microbeta TriLux 1450 scintillation counter. All reagent transfers were conducted using a Hamilton liquid handler. Data were analyzed by non-linear curve-fitting using the program GraphPad Prism 6. Binding data is reported as mean ± s.e.m.

Mutagenesis of the ligand-binding pocket residues and radioligand binding assays {#S19}
--------------------------------------------------------------------------------

Radioligand binding assays were performed as previously described^[@R25]^. Briefly, ligand binding was measured using washed membranes from HEK 293 cells (FreeStyle^™^ 293-F, ThermoFisher, cat. R79007) transiently expressing WT AT~2~R or point mutant AT~2~R constructs. Cells were lysed in buffer (25 mM HEPES, pH 7.5) with protease inhibitor cocktail consisting of AEBSF (GoldBio), E-64, Leupeptin, Aprotinin (AGScientific), and dounce homogenized. Membranes were centrifuged for 15 minutes at 30,000 × g. Total protein concentration was measured by Bradford assay, and membrane pellets were frozen in liquid nitrogen and stored at −80 °C. Binding assays were carried out in a total volume of 0.25 mL in 96-well plates with a binding buffer (140 mM NaCl, 5 mM KCl, 1mM EDTA, 25 mM HEPES, pH 7.4, 0.006% BSA) containing 1 nM \[^3^H\]AngII (American Radiolabeled Chemicals, Inc) for 60 minutes at room temperature. Membranes were harvested over 0.3% polyethyleneimine-treated, 96-well filter mats using a 96-well Filtermate harvester (Perkin Elmer) and washed 3 times with cold buffer (25 mM HEPES, pH 7.5). Filter mats were dried, wax scintillant was melted onto each filter, and radioactivity was counted in a MicroBeta2 TriLux plate scintillation counter (Perkin Elmer). AngII *K~d~* for WT and mutants were determined using homologous competition binding. *K~i~* was determined using \[^3^H\]AngII competition with 12 concentrations of unlabeled ligand (10,000 uM -- 0.01 nM). The data were analyzed by Prism 6.05 (GraphPad Software) to give *K~d~* and *K~i~* values and reported as the mean ± s.e.m.

Compound preparation {#S20}
--------------------

All molecules presented in this manuscript were prepared according to the appropriate literature and/or patent publications: Compounds **1**, **3** (ref. [@R26]), Compounds **2**, **5**, **6**, **10**, **12**, and **14** (ref. [@R27]), Compounds **4** and **11** (ref. [@R64]), Compounds **7--9** (ref. [@R65]), Compound **13** (ref. [@R66]).

Cell lines {#S21}
----------

Sf9 cells were purchased from the American Type Culture Collection. HEK 293 cells were acquired from ThermoFisher. The cell lines have not been authenticated. All cell lines have been tested and shown to be free from mycoplasma.

Data availability {#S22}
-----------------

Atomic coordinates and structure factors for the AT~2~R-Cpd **1**, monoclinic and orthorhombic, and AT~2~R-Cpd **2** structures have been deposited into the Protein Data Bank with accession codes 5UNF, 5UNG, and 5UNH, respectively. All other data are available from the corresponding authors upon reasonable request.

Extended Data {#S23}
=============

![AT~2~R "snake" diagram and protein engineering\
Truncations are shown in grey, disulfide bonds in yellow, ligand-binding residues in red, conserved motifs in green.](nihms857419f5){#F5}

![Radioligand binding assays\
**a, b,** Saturation binding of Cpd **1** and Sar^1^-Ile^8^-AngII. Specific binding of \[^3^H\]-Cpd **1** (a) and \[^125^I\]-Sar^1^-Ile^8^-AngII (b) to the wild-type (open circle) and engineered AT~2~R (closed triangle), representative of two separate experiments; **c**--**e,** Competition binding of Cpd **1** (open circle), Cpd **2** (closed triangle) and AngII (open square) to the wild-type AT~2~R (**c**), engineered AT~2~R (**d**) and wild type AT~1~R (**e**) with \[^125^I\]-Sar^1^-Ile^8^-AngII as a tracer; each point represents the mean ± s.e.m. of two separate experiments, each performed in duplicates.](nihms857419f6){#F6}

![Crystallization of AT~2~R and crystal packing\
**a,** AT~2~R-Cpd **1** crystals grown in a syringe for XFEL data collection. **b,** AT~2~R-Cpd **2** crystals grown in a glass sandwich plate for synchrotron data collection. **c,** Crystal packing in the monoclinic space group (AT~2~R-Cpd **1** and AT~2~R-Cpd **2** structures), side and top views (AT~2~R in green and cyan; BRIL in orange and pink). **d,** Crystal packing in the orthorhombic space group (AT~2~R-Cpd **1** structure), side and top views (AT~2~R in cyan; BRIL in blue). **e,** Different BRIL orientations in the two BRIL-AT~2~R molecules in the asymmetric unit of monoclinic AT~2~R-Cpd **1** structure and AT~2~R-Cpd **2** structure (pink and orange), and in the orthorhombic AT~2~R-Cpd **1** structure (blue) with AT~2~R in cyan, side and top views. Unit cell in (**c**) and (**d**) is outlined in black line.](nihms857419f7){#F7}

![Conserved L\[M\]^3.46^ -- I\[A\]^6.37^ -- Y\[Y\]^7.53^ microswitch and sodium binding pocket in AT~1~R and AT~2~R\
**a,** Comparison of the conserved residue triad between AT~1~R (green, PDB 4YAY) and AT~2~R (cyan) structures, shows a rearrangement of interactions consistent with AT~2~R activation. **b,** Modeling of the AT~2~R in a hypothetical inactive state (cyan), based on the AT~1~R crystal structure template (green) shows that replacement of a large hydrophobic residue in position 6.37, as conserved in most class A GPCRs, to a rare small Ala258^6.37^ in AT~2~R drastically reduces the hydrophobic contact in this region between helices III and VI in the inactive state. **c,d, S**odium binding pocket in AT~2~R (**c**) and AT~1~R (PDB 4YAY) (**d**) is shown as a surface with hydrogen bonds between Asn^7.46^ and Asn^3.35^ as orange spheres. Putative sodium ion in the AT~1~R structure (**d**) is shown as a solid magenta sphere, while the same position in the AT~2~R structure (**c**) is marked as a dotted sphere. Potential sodium-coordinating residues are shown as sticks.](nihms857419f8){#F8}

![Summary of MD simulations\
**a--c,** Conformational stability of AT~2~R structure is illustrated by representative conformations from a total of 4 μs of MD simulations (eight independent 500 ns runs), clustered by RMSD. Traces of distances measured between different helices are shown for apo AT~2~R (**a**) and for the AT~2~R-Cpd **1** complex (**b**). Distances were calculated between the centers of mass of residues Ser79^2.39^-Ile83^2.43^ for helix II, Arg142^3.50^-Val146^3.54^ for helix III, Gln253^6.32^-Met257^6.36^ for helix VI, and Phe325-Lys328 for helix VIII. **d,e,** Conformational stability of helix VIII upon perturbations, using eight starting conformations of helix VIII (**d**) is revealed by RMSD traces (**e**), which all converge by \~250 ns of simulations. RMSD values are calculated for the center of mass of Cα atoms of residues Phe325-Lys328 compared to the crystal structure of AT~2~R. Tick marks on the Y-axis show the starting frame RMSD values. Colored lines are plotted using values averaged over a 500 ps window. **f--h,** Results of MD simulations for a modified AT~2~R model with the backbone of helix VIII aligned with helix VIII from AT~1~R structure (PDB 4YAY). Conformational snapshots of the AT~2~R model (**f**) are shown for every 100 ns (blue to red spectrum) from one of the six independent 700 ns MD simulation runs (simulation 5). Green cartoon shows inactive-state conformation of CCR5 (PDB 4MBS), helix VIII of which was found to be the closest to the final conformations of AT~2~R helix VIII in MD simulations. Intracellular view (**g**) of snapshots from the same MD simulation is shown only t=0 and t=700 ns. Traces of the distance between helices VI and II (**e**, upper curves), calculated between the centers of mass of Cα atoms of residues Gln253^6.32^-Met257^6.36^ in helix VI and residues Ser79^2.39^-Ile83^2.43^ in helix II, show a change from 21 Å (active state) to under 16 Å (inactive state). Traces of the distance between helix VIII and membrane (**e**, lower curves), calculated between the center of mass of Cα atoms of residues R330--V332 and the closest phosphate atoms of lipid molecules, indicate a gradual shift of helix VIII towards the lipid bilayer, with the distance decreasing from \~10 Å to under 3 Å.](nihms857419f9){#F9}

![Electron density for Cpd 1 and Cpd 2\
**a, b,** Cpd **1** can be modeled in two possible conformations, (**a**) and (**b**), with alternative orientations of the benzene and thiophene rings. **c, d,** Cpd **2** can be modeled in two possible conformations, (**c**) and (**d**), with alternative orientations of the benzene and furan rings. 2mFo-DFc electron density (blue mesh) for Cpd **1** contoured at 1 σ, and mFo-DFc density (green mesh -- positive, red mesh -- negative) contoured at 3 σ. The conformations shown in panels (**a**) and (**c**) were used in the final crystal structures because of a slightly better ligand fit and the absence of strong difference mFo-DFc density. Both conformations for each ligand, however, are possible and indistinguishable by docking studies.](nihms857419f10){#F10}

![Ligand binding and cross-docking in AT~2~R and AT~1~R structures\
**a,b,** Docking poses of Cpd **1** (magenta), Cpd **2** (yellow), olmesartan (blue) and ZD7155 (orange) in the crystal structures of AT~2~R (**a**) and AT~1~R (**b**). Receptors are shown in carton representation, ligands are shown as sticks, and hydrogen bonds/salt bridges are shown as dashed lines. **c,** Ligand binding affinities and docking scores for AT~2~R and AT~1~R ligands. Data for the cognate ligands are shown in bold. Inactive state AT~1~R and active-like state of AT~2~R correspond to crystal structures. Active-like state of AT~1~R and inactive state of AT~2~R were modeled based on the crystal structures of AT~2~R and AT~1~R, respectively.](nihms857419f11){#F11}

![Mutagenesis of the AT~2~R ligand-binding pocket\
**a,** Ligand-binding pocket from the AT~2~R-Cpd **1** crystal structure. **b,** Ligand-binding pocket from the AT~1~R-olmesartan crystal structure. **c,** Schematics of interactions between Cpd **1** and AT~2~R residues. **d,** Schematics of interactions between olmesartan and AT~1~R residues. In all panels, residues are colored according to their effect on affinity: more than 100-fold decrease in affinity (orange); 5--100-fold decrease in affinity (yellow); less than 5-fold decrease in affinity (grey). **e,** Effects of single residue mutations in the AT~2~R ligand-binding pocket on the ligand binding affinities. Values represent mean ± s.e.m. with the number of experiments shown in parenthesis.](nihms857419f12){#F12}

###### 

Data collection and refinement statistics (molecular replacement).

                                       AT~2~R-Cpd 1 (XFEL)                                AT~2~R-Cpd 2 (Synchrotron)                                   
  ------------------------------------ -------------------------------------------------- ---------------------------- ----------------------- ------- -------
  Space group                          P2~1~                                              P2~1~22~1~                   P2~1~                           
  Unit cell parameters                                                                                                                                 
  *a,b,c* (Å)                          77.4,69.1,90.1                                     70.3, 78.8, 93.4             78.4,68.2, 89.1                 
  α,β,γ (°)                            90.0, 104.3, 90.0                                  90.0, 90.0, 90.0             90.0, 104.3, 90.0               
  **Data collection**                                                                                                                                  
  Number of collected frames           2,701,530                                          2,701,530                    *N.A..*                         
  Number of hits/indexed images        175,241/22,774                                     175,241/15,804               *N.A..*                         
  Number of total/unique reflections   1,412,692/22,934                                   1,139,069/13,330             64,806/18,479                   
  Resolution (Å)                       30-2.8 (2.9-2.8)[\#](#TFN2){ref-type="table-fn"}   30-2.8 (2.9-2.8)             47.30-2.9 (3.06-2.90)           
  Completeness (%)                     100(100)                                           100(100)                     91.0(83.2)                      
  Multiplicity                         61.6(16.3)                                         85.5 (27.2)                  3.5 (2.5)                       
  *llσ(l)*                             4.1 (0.8)                                          4.9(1.0)                     5.8(1.8)                        
  *CC\**                               0.98 (0.24)                                        0.99 (0.36)                  0.99 (0.84)                     
  *R~split~ Or R~merge~*(%)            16.4(172)                                          14.8(124)                    12.5 (44.2)                     
  **Refinement**                                                                                                                                       
  Resolution (Å)                       29.57-2.80                                         28.96-2.80                   30.00-2.90                      
  Number of reflections/test set       22,906/1,118                                       13,269/691                   18,462/906                      
  *R~work~/R~free~*                    0.227/0.256                                        0.241/0.262                  0.216/0.259                     
  Number of atoms                                                                                                                                      
                                       A                                                  B                                                    A       B
   Receptor/BRIL                       3,103                                              3,048                        3,195                   2,983   2,800
   Ligand                              46                                                 46                           46                      47      47
   Lipid and other                     0                                                  0                            25                      0       0
  Wilson *B*-factors (Å^2^)            90.8                                               80.9                         79.1                            
  Mean overall *B* value (Å^2^)                                                                                                                        
                                       A                                                  B                                                    A       B
   Receptor                            131.5                                              84.6                         82.1                    72.0    114.2
   BRIL                                141.7                                              107.8                        86.1                    106.1   138.6
   Ligand                              126.5                                              64.2                         63.8                    62.1    112.7
   Lipid and other                     **-**                                              \-                           82.6                    **-**   **-**
  R.m.s bonds (Å)/angles (°)           0.010/0.90                                         0.009/0.92                   0.009/0.97                      

Data collected from 47 crystals were used for the AT~2~R-Cpd **2** structure determination.

Numbers in parentheses represent values from the highest resolution shell.

###### 

SAR for quinazolinone-biphenyltetrazole derivatives in AT~2~R and AT~1~R.

  -------- ---------------- -- --------------- ------------- --------
  **1**    **Ethyl**           0.34 ± 0.06     184 ± 50      530x
  **2**    ***n*-Propyl**      0.35 ± 0.05     3.72 ± 0.03   11x
  **3**    **Methyl**          1.7 ± 0.4       700 ± 200     410x
  **4**    ***n*-Propyl**      0.65 ± 0.01     1.8 ± 0.2     2.8x
  **5**                        11.5 ± 0.5      37 ± 3        3.2x
  **6**                        120 ± 50        450 ± 20      3.8x
  **7**    ***n*-Propyl**      1.7 ± 0.5       10.4 ± 1.7    6.1x
  **8**    ***n*-Propyl**      10.9 ± 0.1      9.90 ± 0.01   0.9x
  **9**    ***n*-Propyl**      1,790 ± 150     1.6 ± 0.1     0.001x
  **10**   ***n*-Propyl**      4.9 ± 0.2       12.9 ± 2.8    2.6x
  **11**   ***n*-Propyl**      4.1 ±0.8        6.7 ± 0.9     1.6x
  **12**   ***n*-Propyl**      18.8 ± 0.1      17.3 ± 4.3    0.9x
  **13**   ***n*-Propyl**      2,990 ± 80      16.7 ± 10.4   0.006x
  **14**   **Methyl**          5,300 ± 2,400   360 ± 80      0.07x
  -------- ---------------- -- --------------- ------------- --------

Competition binding assay with \[^125^I\]-Sar^1^-Ile^8^-AngII as a tracer; each point represents the mean ± s.e.m. of two separate experiments, each performed in duplicates.
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![Active-like conformation of AT~2~R\
**a,** Overall receptor architecture. Cpd **1** is shown as spheres with carbon atoms in magenta, nitrogen in blue, oxygen in red, and sulfur in yellow. Membrane boundaries as defined by the OPM web server ([www.opm.phar.umich.edu](www.opm.phar.umich.edu)) are shown as red lines. **b--e,** Structural comparison of the active-like AT~2~R (cyan) with the inactive AT~1~R (green, PDB 4YAY), and active G protein-bound β~2~AR (yellow, PDB 3SN6) viewed from within the membrane **(b)**, the extracellular side **(d)**, and the intracellular side with helix VIII removed **(e)**. The magnified region in **(c)** shows details of microswitches in the conserved motifs. The backbone of AT~2~R is shown in cyan cartoon, while distinct inactive position of AT~1~R helix VII is shown in green. Red arrows indicate conformational changes associated with receptor activation.](nihms857419f1){#F1}

![Helix VIII blocks putative G protein/β-arrestin binding site of AT~2~R\
**a, b,** Varied positions of helix VIII in different GPCRs shown as cartoons. AT~2~R is in cyan with helix VIII colored magenta, AT~1~R (PDB 4YAY) in green, NTSR1 (PDB 4GRV) in red, G protein-bound β~2~AR (PDB 3SN6) in yellow, and arrestin-bound rhodopsin in blue (PDB 4ZWJ), viewed from within the membrane (**a**) and from the intracellular side (**b**). **c,** Shared interaction sites of AT~2~R 7TM domain (grey surface) for the helix VIII of AT~2~R (magenta), the C-terminus of G protein (red), and the finger loop of arrestin (yellow). **d,** interactions between helix VIII (magenta) and helices III, V, VI (cyan) in AT~2~R. Side chains of helix VIII not resolved in the crystal structure are shown with grey carbon atoms.](nihms857419f2){#F2}

![Ligand selectivity between AT~1~R and AT~2~R\
**a,** Comparison of binding modes of different ligands in AT~1~R (green) and AT~2~R (cyan) binding pockets. The side chains in contact with ligands are shown as sticks with labels representing AT~2~R and AT~1~R residues in the corresponding positions. **b, c,** Comparison of the ligand-binding pockets between AT~2~R (cyan) and AT~1~R (green). Receptors are shown in the same orientation of transmembrane helices with the conserved Arg^ECL2^ (Arg167^ECL2^ in AT~1~R and Arg182 ^ECL2^ in AT~2~R) aligned. The ligands are shown as thick sticks, with carbon atoms of the AT~2~R ligands Cpd **1** in magenta, Cpd **2** in yellow, the AT~1~R ligands ZD7155 in orange, and olmesartan in blue.](nihms857419f3){#F3}

![Docking and SAR analysis of quinazolinone-biphenyltetrazole derivatives in AT~2~R and AT~1~R\
**a, b,** Docking poses for compounds from [Extended Data Table 2](#T2){ref-type="table"} in the crystal structures of AT~2~R (**a**) and AT~1~R (**b**). Key side chains are shown as sticks. The ligands from the co-crystal structures, Cpd **1** for AT~2~R and olmesartan for AT~1~R, are shown as sticks with magenta and cyan carbons, respectively. The docked SAR analogs are shown as thin sticks with orange carbons. **c, d,** Schematics of interactions for docked compounds into AT~2~R (**c**) and AT~1~R (**d**) crystal structures. Residues conserved between AT~2~R and AT~1~R are shown in red, non-conserved residues are shown in blue. Well-defined hydrophobic pockets are shown as blue shapes, the loose hydrophobic pocket of AT~1~R is shown as a green shape.](nihms857419f4){#F4}
